Key facts
- Johnson & Johnson will acquire Firefly Bio for $1 billion in cash.
- The acquisition aims to expand Johnson & Johnson's cancer drug pipeline.
- Firefly Bio's Firelink platform uses antibodies to deliver protein-degrading drugs directly into cancer cells.
- The platform targets tumors with KRAS gene mutations, considered difficult to treat.
- The transaction is expected to close later this year.
Johnson & Johnson announced on Monday its agreement to acquire Firefly Bio for $1 billion in cash, a move designed to bolster its oncology pipeline. The biotech firm's Firelink platform utilizes antibodies to deliver protein-degrading drugs directly to cancer cells, a technology J&J believes can target tumors while sparing healthy tissue. This approach is particularly aimed at tumors with KRAS gene mutations, which have historically been challenging to treat. John Reed, executive vice president of innovative medicine, research & development at J&J, stated that the platform addresses a significant unmet need for patients with KRAS-driven cancers, who currently face limited treatment options and short survival rates. The transaction is anticipated to conclude by the end of the year.